Wason

The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected

*Statistical Methods in Medical Research* 2015; 24(6):909-919

Accelerated BEP: A phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour

*British Journal of Cancer* 2011; 105(6):766-772

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

*Nature* 2011; 476(7359):214-219

Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points

*European Journal of Cancer* 2011; 47(7):983-989

Comparison of multimarker logistic regression models, with application to a genomewide scan of schizophrenia

*BMC Genetics* 2010; 11:80

A non-synonymous SNP within membrane metalloendopeptidase-like 1 (MMEL1) is associated with multiple sclerosis

*Genes and Immunity* 2010; 11(8):660-664

What role for genetics in the prediction of multiple sclerosis?

*Annals of Neurology* 2010; 67(1):3-10

Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor

*European Journal of Human Genetics* 2009; 17(10):1309-1313